Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons

Mario Clerici, Stefania Piconi, Claudia Balotta, Daria Trabattoni, Amedeo Capetti, Maria Luisa Fusi, Stefania Ruzzante, Renato Longhi, Maria Chiara Colombo, Mauro Moroni, Francesco Milazzo

Research output: Contribution to journalArticle

Abstract

The effects of pentoxifylline on immunologic and virologic parameters were evaluated in 10 human immunodeficiency virus-infected patients not receiving antiretroviral treatment. Patients were asymptomatic, had 300-500 CD4 cells/μL, and received pentoxifylline (1200 rag/day orally) for 4 months. Peripheral blood mononuclear cells were tested before and at five time points during therapy. A transient increase in CD4 cells was observed in 8 of 9 patients, and CD8 cells increased in 7 of 9 patients. These increases were negatively correlated with susceptibility to in vitro mitogen-stimulated apoptotic cell death. Pentoxifylline had a temporary effect on mitogen- stimulated cytokine production; thus, interferon-γ, interleukin (IL)-2, tumor necrosis factor-α, and lymphotoxin increased more than IL-10. Pentoxifylline also potentiated antigen-stimulated IL-2 production and proliferation in 8 of 9 patients and induced significant but transient decreases in plasma viremia in 7 of 9 patients. These preliminary findings suggest that pentoxifylline in vivo has an interesting but temporary influence on both immunologic and virologic parameters.

Original languageEnglish
Pages (from-to)1210-1215
Number of pages6
JournalJournal of Infectious Diseases
Volume175
Issue number5
Publication statusPublished - 1997

    Fingerprint

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Clerici, M., Piconi, S., Balotta, C., Trabattoni, D., Capetti, A., Fusi, M. L., Ruzzante, S., Longhi, R., Colombo, M. C., Moroni, M., & Milazzo, F. (1997). Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. Journal of Infectious Diseases, 175(5), 1210-1215.